Search Results

You are looking at 31 - 40 of 57 items for :

  • "myeloid growth factors" x
  • User-accessible content x
Clear All
Full access

11 11 10 10 xlix xlix xlix xlix 011xlix 10.6004/jnccn.2013.0151 Moving Forward With Myeloid Growth Factors Crawford Jeffrey MD 10 2013 11 11 10 10 1181 1181 1182 1182 0111181 10.6004/jnccn.2013.0139 Imatinib-Induced Bone Edema: Case Report

Full access

Antiemesis, Head and Neck Cancers, and Myeloid Growth Factors NCCN is pleased to offer a pocket-sized version of the following NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis Head and Neck Cancers Myeloid Growth

Full access

, MPH Neuner Joan M. a b MD, MPH Pezzin Liliana E. a b PhD, JD 12 2017 15 15 12 12 1509 1509 1517 1517 10.6004/jnccn.2017.7021 Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology Crawford Jeffrey

Full access

jnccn195018 10.6004/jnccn.2019.5018 New Biosimilar Approvals for Myeloid Growth Factors and Anemia Lyman Gary H. MD, MPH, FASCO, FACP, FRCP 05 2019 17 17 5.5 5.5 622 622 624 624 jnccn195016 10.6004/jnccn.2019.5016 Developments in Systemic Therapy for

Full access

Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use Weycker Derek a PhD Li Xiaoyan b PhD Barron Rich b MS Wu Hongsheng a PhD Morrow P.K. b MD Xu Hairong b MD, PhD Reiner Maureen

Full access

820 820 0120817 10.6004/jnccn.2014.0197 Treatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How? Crawford Jeffrey MD Rodgers George M. MD, PhD 05 2014 12 12 5S 5S 821 821 824 824 0120821 10.6004/jnccn

Full access

Abiy Agiro, Andrea DeVries, Jennifer Malin and Michael J. Fisch

support tool implemented by one national payer across 9 intervention states for patients with breast cancer. This tool was developed using NCCN and ASCO guidelines pertaining to myeloid growth factor use. We present differences in population-level changes

Full access

Gary H. Lyman

Guidelines in Oncology: Myeloid Growth Factors . J Natl Compr Canc Netw 2007 ; 5 : 188 – 202 . 10 Smith TJ Khatcheressian J Lyman GH . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page and Chun Chao

(CRC); bendamustine with or without rituximab (B±R) for non-Hodgkin's lymphoma (NHL); and lenalidomide with or without dexamethasone for multiple myeloma (MM). When this study was initiated, TC was established by the NCCN Myeloid Growth Factors

Full access

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia and Gary H. Lyman

-stimulating factor (CSF) prophylaxis in cycle 1 was consistently high for the 3 breast cancer regimens with a high risk (>20%) of FN according to the NCCN Guidelines for Myeloid Growth Factors 29 (from 89.1% for dose-dense AC followed by paclitaxel every 2 weeks to